Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?

Diabetes, Obesity and Metabolism

Volumn 10, Issue 5, 2008, Pages 353-366

  Liew, A ^a,b   Mcdermott, J H ^a,b   Barry, F ^b   O'Brien, Timothy ^a,b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Diabetes mellitus; Endothelial progenitor cells; Vascular diseases

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; VALSARTAN;

ACUTE HEART INFARCTION; ANGIOGENESIS; ARTERY DISEASE; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; CELL COUNT; CELL FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DYSLIPIDEMIA; EMBRYO DEVELOPMENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIMB ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 42149189427     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00754.x     Document Type: Review

References (126)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
2. Kalka C et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97: 3422-3427.
3. Kubota Y et al. Transplanted endothelial progenitor cells augment the survival areas of rat dorsal flaps. Cell Transplant 2003; 12: 647-657.
4. Griese DP et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108: 2710-2715.
5. He T et al. Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. Stroke 2004; 35: 2378-2384.
6. Takahashi M et al. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng 2004; 10: 771-779.
7. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005; 23: 1831-1837.
8. Chen JZ et al. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond) 2004; 107: 273-280.
9. Kondo T et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004; 24: 1442-1447.
10. Hill JM et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
11. Werner N et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
12. Schmidt-Lucke C et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-2987.
13. Gulati R et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93: 1023-1025.
14. Eggermann J et al. Endothelial progenitor cell culture and differentiation in vitro: A methodological comparison using human umbilical cord blood. Cardiovasc Res 2003; 58: 478-486.
15. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
16. Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc Med 2004; 14: 318-322.
17. Ingram DA et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-2760.
18. Walenta K, Friedrich EB, Sehnert F, Werner N, Nickenig G. In vitro differentiation characteristics of cultured human mononuclear cells-implications for endothelial progenitor cell biology. Biochem Biophys Res Commun 2005; 333: 476-482.
19. Bellik L, Ledda F, Parenti A. Morphological and phenotypical characterization of human endothelial progenitor cells in an early stage of differentiation. FEBS Lett 2005; 579: 2731-2736.
20. Hur J et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-293.
21. Liew A, Barry F, O'Brien T. Endothelial progenitor cells: Diagnostic and therapeutic considerations. Bioessays 2006; 28: 261-270.
22. Zhang SJ et al. Adult endothelial progenitor cells from human peripheral blood maintain monocyte/macrophage function throughout in vitro culture. Cell Res 2006; 16: 577-584.
23. Romagnani P et al. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 2005; 97: 314-322.
24. Urbich C et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-2516.
25. Fan CL et al. Therapeutic neovascularization by autologous transplantation with expanded endothelial progenitor cells from peripheral blood into ischemic hind limbs. Acta Pharmacol Sin 2005; 26: 1069-1075.
26. Yoon CH et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: The role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112: 1618-1627.
27. Hoetzer GL et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. Am J Cardiol 2007; 99: 46-48.
28. Hoetzer GL, Van Guilder GP, Irmiger H, Keith RS, Stauffer BL, Desouza CA. Aging, exercise and endothelial progenitor cell clonogenic and migratory capacity in men. J Appl Physiol 2006.
29. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
30. Tao J, Wang Y, Yang Z, Tu C, Xu MG, Wang JM. Circulating endothelial progenitor cell deficiency contributes to impaired arterial elasticity in persons of advancing age. J Hum Hypertens 2006; 20: 490-495.
31. Seeger FH et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111: 1184-1191.
32. Krankel N et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 2005; 25: 698-703.
33. Kuki S et al. Hyperglycemia accelerated endothelial progenitor cell senescence via the activation of p38 mitogen-activated protein kinase. Circ J 2006; 70: 1076-1081.
34. Krankel N et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 2005.
35. Ii M et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 2006; 98: 697-704.
36. Tamarat R et al. Impairment in ischemia-induced neovascularization in diabetes: Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol 2004; 164: 457-466.
37. Segal MS et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006; 55: 102-109.
38. Fadini GP et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006.
39. Loomans CJ et al. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53: 195-199.
40. Asnaghi V, Lattanzio R, Mazzolari G, Pastore MR, Ramoni A, Maestroni A, et al. Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy. Diabetologia 2006; 49: 1109-1111.
41. Tepper OM et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
42. Fadini GP et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457.
43. Pistrosch F et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005; 183: 163-167.
44. Rosso A et al. p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem 2006; 281: 4339-4347.
45. Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care 2006; 29: 714-716.
46. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 2006; 20: 546-552.
47. Butler JM et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 2005; 115: 86-93.
48. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis 2005; 187: 423-432.
49. Kim W et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 2006; 70: 1052-1057.
50. Wang X, Zhu J, Chen J, Shang Y. Effects of nicotine on the number and activity of circulating endothelial progenitor cells. J Clin Pharmacol 2004; 44: 881-889.
51. Heeschen C, Chang E, Aicher A, Cooke JP. Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J Am Coll Cardiol 2006; 48: 2553-2560.
52. Rehman J et al. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol 2004; 43: 2314-2318.
53. Laufs U et al. Running exercise of different duration and intensity: effect on endothelial progenitor cells in healthy subjects. Eur J Cardiovasc Prev Rehabil 2005; 12: 407-414.
54. Laufs U et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004; 109: 220-226.
55. Kusuyama T et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci 2006; 102: 96-102.
56. Wang CH et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: A new paradigm in glitazone pleiotropy. Circulation 2004; 109: 1392-1400.
57. Verma S et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-2067.
58. Suh W et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 2004; 321: 65-71.
59. Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006; 26: 2476-2482.
60. Wang CH et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 2006; 152: 1051 e1-8.
61. Wang X, Chen J, Tao Q, Zhu J, Shang Y. Effects of ox-LDL on number and activity of circulating endothelial progenitor cells. Drug Chem Toxicol 2004; 27: 243-255.
62. Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized low-density lipoprotein inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin Exp Pharmacol Physiol 2003; 30: 665-670.
63. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol 2004; 31: 407-413.
64. Assmus B et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-1055.
65. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond) 2004; 107: 273-280.
66. Delva P et al. Endothelial progenitor cells in patients with essential hypertension. J Hypertens 2007; 25: 127-132.
67. Dimmeler S et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397.
68. Llevadot J et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
69. Zhu JH, Tao QM, Chen JZ, Wang XX, Shang YP. Statins contribute to enhancement of the number and the function of endothelial progenitor cells from peripheral blood. Sheng Li Xue Bao 2004; 56: 357-364.
70. Landmesser U et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939.
71. Vasa M et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-2890.
72. Walter DH et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
73. Rupp S et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol 2004; 99: 61-68.
74. Noor R, Shuaib U, Wang CX, Todd K, Ghani U, Schwindt B, et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 2006.
75. Pellegatta F et al. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. Int J Mol Med 2006; 17: 203-208.
76. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1144-1149.
77. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2004; 18: 203-209.
78. Bahlmann FH et al. Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-529.
79. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23: 97-104.
80. Wang CH et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol 2006; 41: 34-43.
81. Boyle AJ et al. Additive effects of endothelial progenitor cells combined with ACE inhibition and b-blockade on left ventricular function following acute myocardial infarction. J Renin Angiotensin Aldosterone Syst 2005; 6: 33-37.
82. Janssens S et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. Lancet 2006; 367: 113-121.
83. Kang HJ et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: The MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006; 114: I145-I151.
84. Strauer BE et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918.
85. Wollert KC et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-148.
86. Erbs S et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: First randomized and placebo-controlled study. Circ Res 2005; 97: 756-762.
87. Strauer BE et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: The IACT Study. J Am Coll Cardiol 2005; 46: 1651-1658.
88. Perin EC et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-2302.
89. Huang P et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160.
90. Saigawa T et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 2004; 68: 1189-1193.
91. Tateishi-Yuyama E et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
92. Tse HF et al. Safety of catheter-based intramyocardial autologous bone marrow cells implantation for therapeutic angiogenesis. Am J Cardiol 2006; 98: 60-62.
93. Naruse K et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 2005; 54: 1823-1828.
94. Zhou B et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost 2006; 4: 993-1002.
95. Korbling M et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: A novel blood cell component for therapeutic vasculogenesis. Transfusion 2006; 46: 1795-1802.
96. Zbinden S, Zbinden R, Meier P, Windecker S, Seiler C. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 1636-1642.
97. Hill JM et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 1643-1648.
98. Keswani SG et al. Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen 2004; 12: 497-504.
99. Asai J et al. Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation 2006; 113: 2413-2424.
100. Asai J, Takenaka H, Katoh N, Kishimoto S. Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J Invest Dermatol 2006; 126: 1159-1167.
101. Ebrahimian TG et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol 2006; 169: 719-728.
102. Marchetti V et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006; 55: 2231-2237.
103. Gadau S et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006; 49: 405-420.
104. Tse HF et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-49.
105. Yamamoto K et al. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: Therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol 2004; 24: E192-e196.
106. Fuchs S et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study. J Am Coll Cardiol 2003; 41: 1721-1724.
107. Kang HJ et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 2004; 363: 751-756.
108. Silva GV et al. Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J 2004; 31: 214-219.
109. Perin E. Transendocardial injection of autologous mononuclear bone marrow cells in end-stage ischemic heart failure patients: One-year follow-up. Int J Cardiol 2004; 95 (Suppl. 1): S45-S46.
110. Assmus B et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-3017.
111. Lemstrom KB et al. Role of angiogenic growth factors in transplant coronary artery disease. Ann Med 2004; 36: 184-193.
112. Ito H et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999; 59: 5875-5877.
113. Conklin BS, Wu H, Lin PH, Lumsden AB, Chen C. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized heparin-coated vascular graft. Artif Organs 2004; 28: 668-675.
114. Murasawa S et al. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 2002; 106: 1133-1139.
115. Takahashi T et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
116. Ishizawa K et al. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun 2004; 324: 276-280.
117. De Falco E et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004; 104: 3472-3482.
118. Henrich D et al. Serum derived from multiple trauma patients promotes the differentiation of endothelial progenitor cells in vitro: Possible role of transforming growth factor-beta1 and vascular endothelial growth factor165. Shock 2004; 21: 13-16.
119. Kalka C et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-1202.
120. Bahlmann FH et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648-1652.
121. Sugawara J et al. Circulating endothelial progenitor cells during human pregnancy. J Clin Endocrinol Metab 2004; 90: 1845-1848.
122. Chen J et al. Effects of Ginkgo biloba extract on number and activity of endothelial progenitor cells from peripheral blood. J Cardiovasc Pharmacol 2004; 43: 347-352.
123. Palumbo B, Palumbo R, Sinzinger H. Radioidine therapy temporarily increases circulating endothelial cells and decreases endothelial progenitor cells. Nucl Med Rev Cent East Eur 2003; 6: 123-126.
124. Foresta C et al. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005; 17: 377-380.
125. Zhu JH et al. Effects of puerarin on number and activity of endothelial progenitor cells from peripheral blood. Acta Pharmacol Sin 2004; 25: 1045-1051.
126. Butzal M et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004; 300: 65-71.